Meclofenoxate

Meclofenoxate.svg

Nootropic drug

Meclofenoxate
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration	Oral
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	51-68-3
PubChem	4054
DrugBank	DB08991
ChemSpider	3915
KEGG	D05029

Meclofenoxate, also known as centrophenoxine, is a nootropic drug used to improve cognitive function and treat symptoms of senile dementia and Alzheimer's disease. It is marketed under the brand name Lucidril.

Mechanism of Action

Meclofenoxate is an ester of dimethylaminoethanol (DMAE) and p-chlorophenoxyacetic acid (pCPA). It is believed to work by increasing the levels of acetylcholine in the brain, a neurotransmitter associated with memory and learning. Additionally, it may enhance the uptake of glucose and oxygen by the brain, thereby improving neuronal energy metabolism.

Uses

Meclofenoxate is primarily used in the treatment of cognitive disorders such as senile dementia and Alzheimer's disease. It is also used as a nootropic to enhance memory, learning, and overall cognitive function in healthy individuals.

Side Effects

Common side effects of meclofenoxate include nausea, gastrointestinal discomfort, and insomnia. In rare cases, it may cause allergic reactions or hypertension.

Dosage

The typical dosage of meclofenoxate varies depending on the condition being treated. For cognitive enhancement, doses range from 250 mg to 1000 mg per day, divided into two or three doses. For the treatment of dementia, higher doses may be required, as prescribed by a healthcare provider.

History

Meclofenoxate was first developed in the 1950s and has been used in various countries for the treatment of cognitive disorders. It has gained popularity as a nootropic in recent years due to its potential cognitive-enhancing effects.

See Also

• Nootropic
• Cognitive function
• Senile dementia
• Alzheimer's disease
• Acetylcholine

References

   This article is a medical stub. You can help WikiMD by expanding it!